Market Research Logo

Global Depressive Disorder Market: Industry Analysis & Outlook (2016-2020)

Global Depressive Disorder Market: Industry Analysis & Outlook (2016-2020)

Depression is a serious mood disorder, affecting the ability to think, feel, and handle situations like sleeping, eating, or working. It is a mood disorder that causes a persistent feeling of sadness and loss of interest. It builds up a very negative perspective in the way of thinking in every single thing and damages a person’s ability to see brighter versions of any situation in life. It is of various types like major depressive disorder (MDD), perinatal depression, psychotic depression, seasonal depression and bipolar depression.

To be diagnosed with depression, the symptoms must be present for at least two weeks. It may require long-term treatment for years. There is no single cause of depression; it is likely an outcome from combinations of genetic, biochemical, environmental and physiological factors. There are several ways of treating depression depending upon each individual’s characteristics & symptoms. Most people feel better with medication, psychological counseling or both.

The global depressive disorder market is expected to grow and overcome falling revenues due to patent expiry with better innovative drugs and therapies. The US has highest depression disorder prevalence along with highest prevalence of bipolar depression & schizophrenia. With growing awareness and better access to medical facilities, the depressive disorder market is expected to grow worldwide, especially in Asia-Pacific region.

The key factors driving the growth of the depressive disorder market includes increased smoking prevalence, rising healthcare expenditure, growing female population, increasing spending on medicines and rising number of prescription drugs. However, there are certain factors hindering the growth of the market like patent expiry, severe side effects of drugs, and tough regulations. Major trends of the market include novel drug approvals, major drugs in pipeline, and growing public awareness.

The report offers an in-depth analysis of the “Global Depressive Disorder Market” segmented into global and regional markets. Competition is concentrated in the hands of few major pharmaceutical companies out of which Pfizer Inc., AstraZeneca, Eli Lilly and company, and Lundbeck have been covered in the report."


1. Market Overview
1.1 Introduction
1.2 Types
Table 1: Types of Depression
1.3 Causes & Symptoms
Table 2: Causes & Symptoms of Depression
2. Global Market
2.1 Global Depressive Disorder Market by Value
Table 3: Global Depressive Disorder Market by Value (2010-2015)
2.2 Global Depressive Disorder Market Forecast by Value
Table 4: Global Depressive Disorder Market Forecast by Value (2016-2020)
2.3 Global Depressive Disorder Market by Region
Table 5: Global Depressive Disorder Market by Region (2015)
2.4 Global Anti-Depressant Drug Market by Value
Table 6: Global Anti-Depressant Drug Market by Value (2010-2015)
2.5 Global Anti-Depressant Drug Market Forecast by Value
Table 7: Global Anti-Depressant Drug Market Forecast by Value (2016-2020)
2.6 Global Anti-Psychotic Drug Market by Value
Table 8: Global Anti-Psychotic Drug Market by Value (2010-2015)
2.7 Global Anti-Psychotic Drug Market Forecast by Value
Table 9: Global Anti-Psychotic Drug Market Forecast by Value (2016-2020)
3. Regional Markets
3.1 The US
3.1.1 The US Depressive Disorder Market Forecast by Value
Table 10: The US Depressive Disorder Market Forecast by Value (2015-2020)
3.1.2 The US Mental Health Drug Prescription by Volume
Table 11: The US Mental Health Drug Prescription by Volume (2011-2015)
3.1.3 The US Depressive Disorder Patient Prevalence Forecast
Table 12: The US Depressive Disorder Patient Prevalence Forecast (2016-2020)
3.1.4 The US Bipolar Depression Patient Prevalence Forecast
Table 13: The US Bipolar Depression Patient Prevalence Forecast (2016-2020)
3.1.5 The US Bipolar Depression Addressable Population Forecast
Table 14: The US Bipolar Depression Addressable Population Forecast (2016-2020)
3.1.6 The US Schizophrenia Patient Prevalence Forecast
Table 15: The US Schizophrenia Patient Prevalence Forecast (2016-2020)
3.1.7 The US Schizophrenia Addressable Population Forecast
Table 16: The US Schizophrenia Addressable Population Forecast (2016-2020)
3.2 Europe
3.2.1 European Depression Disorder Market Forecast by Value
Table 17: European Depression Disorder Market Forecast by Value (2015-2020)
3.2.2 European Bipolar Depression Patient Prevalence Forecast
Table 18: European Bipolar Depression Patient Prevalence Forecast (2016-2020)
3.2.3 European Bipolar Depression Addressable Population Forecast
Table 19: European Bipolar Depression Addressable Population Forecast (2016-2020)
3.2.4 European Schizophrenia Patient Prevalence Forecast
Table 20: European Schizophrenia Patient Prevalence Forecast (2016-2020)
3.2.5 European Schizophrenia Addressable Population Forecast  
Table 21: European Schizophrenia Addressable Population Forecast (2016-2020)
3.3 China
3.3.1 China Anti-Depressant Drug Market by Value
Table 22: China Anti-Depressant Drug Market by Value (2010-2015)
3.3.2 China Anti-Depressant Drug Market Forecast by Value
Table 23: China Anti-Depressant Drug Market Forecast by Value (2016-2020)
3.3.3 China Anti-Psychotic Drug Market by Value
Table 24: China Anti-Psychotic Drug Market by Value (2010-2015)
3.3.4 China Anti-Psychotic Drug Market Forecast by Value
Table 25: China Anti-Psychotic Drug Market Forecast by Value (2016-2020)
4. Market Dynamics
4.1 Key Trends & Developments
4.1.1 Novel Drug Approvals
Table A: Novel Drug Approvals for Depression Disorder (2015)
4.1.2 Rapid Acting Depression Drugs in Development
Table B: Major Rapid Acting Depression Drugs in Development (2015)
4.1.3 Direct-to-Customer Advertising
4.1.4 Growing Public Awareness
4.2 Growth Drivers
4.2.1 Increasing Sales of Prescription Drugs
Table 26: Increasing Sales of Prescription Drugs (2010-2015)
4.2.2 Increased Spending on Medicines
Table 27: Global Spending on Medicines (2010-2020E)
Table 28: Total Spending on Medicines in the US (2010-2015)
4.2.3 Increased Smoking Prevalence
Table 29: Global Cigarette Consumption (1940-2015)
4.2.4 Rising Spending on Public Health Programs
4.2.5 Rising Global Health Expenditure
Table 30: Global Healthcare Expenditure (2009-2015)
4.2.6 Increasing Female Population Worldwide
Table 31: Global Female Population (2010-2015)
4.3 Challenges
4.3.1 Patent Expiry
4.3.2 Tough Drug Regulations
4.3.3 Severe Side-Effects
Table C: Severe Side-Effects of Depression Disorder Drugs
5. Competitive Landscape
5.1 Global Depressive Disorder Market
5.1.1 Revenue Comparison
Table 32: Global Depressive Disorder Market Revenue Comparison (2015)
5.2 Global Anti-Depressants Market
5.2.1 Market Share Comparison
Table 33: Global Anti-Depressant Market Share by Drugs (2015)
5.2.2 Revenue Comparison
Table 34: Global Anti-Depressant Drug Revenue Comparison (2018)
5.2.3 Product Comparison
Table D: Global Anti-Depressants Market Comparison by Product Profile (2015)
5.3 Global Anti-Psychtoics Market
5.3.1 Market Share Comparison 
Table 35: Global Anti-Psychotic Market Share by Drugs (2015)
5.3.2 Revenue Comparison
Table 36: Global Anti-Psychotic Drug Revenue Comparison (2020)
5.3.3 Product Comparison
Table E: Global Anti-Psychotics Market Comparison by Product Profile (2015)
6. Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Overview
Table 37: Pfizer Inc. Revenue by Segment (2015)
6.1.2 Financial Overview
Table 38: Pfizer Inc. Revenue and Net Income (2012-2015)
6.1.3 Business Strategies
Table F: New Products of Pfizer with FDA Approval (2015/2016)
6.2 AstraZeneca
6.2.1 Business Overview
Table 39: AstraZeneca Revenue by Segment (2015)
6.2.2 Financial Overview
Table 40: AstraZeneca’s Revenue (2012-2015)
6.2.3 Business Strategies
Table G: Approvals and Upcoming Drugs (2015)
6.3 Eli Lilly and Company
6.3.1 Business Overview
Table 41: Eli Lilly Revenue Share by Segments (2015)
6.3.2 Financial Overview
Table 42: Eli Lilly Revenue and Net Income (2011-2015)
6.3.3 Business Strategies
6.4 Lundbeck
6.4.1 Business Overview
Table43: Lundbeck’s Key Therapeutic Areas (2015)
Table 44: Lundbeck’s Revenue Share by Products (2015)
6.4.2 Financial Overview
Table 45: Lundbeck’s Revenue and Net Income (2011-2015)
6.4.3 Business Strategies
Table 46: Lundbeck’s Research & Development Expenses (2011-2015)
Table H: Lundbeck’s New Drugs in Development (2015)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report